Randomized phase III trial of adjuvant chemo-immunotherapy with dendritic cells and activated killer cells in patients with resected primary lung cancer patients
Phase 3
Recruiting
- Conditions
- Primary lung cancer
- Registration Number
- JPRN-UMIN000007525
- Lead Sponsor
- Chiba Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
1 with other active cancer 2 with viral infection (HIV,HBS,HCV) 3 small cell lung cancer( combied SCLC are included for the study)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 year survival,5 year survival
- Secondary Outcome Measures
Name Time Method recurrence free survival, safety, seide effect